ClinicalTrials.gg
Not yet recruitingNCT07860450SAPPHIREUpdated Oct 19, 2026

Two Part (Phase1b/ Phase3) Trial of Subcutaneous Dostarlimab Plus Carboplatin-Paclitaxel in Participants With Primary Advanced or Recurrent Endometrial Cancer

A Phase 3 interventional study of Dostarlimab and Carboplatin and paclitaxel in Endometrial Carcinoma and Neoplasms, Endometrial, sponsored by GlaxoSmithKline. Not yet recruiting. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-19.

Sponsored by GlaxoSmithKline · Phase 3, Interventional, and Treatment

Updated Oct 19, 2026Enrollment updatedDesign changed+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
378
Allocation
Randomized
Ages
18 Years and older
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 18 studies testing dostarlimab in Endometrial Neoplasms — 12 open to participants now, 17 under way, 3 of them phase 3. dostarlimab · Endometrial Neoplasms.

Planned enrollment
Largest of 18
378 · median 46
Started
2026
with 2 others
Phase 3
3 of 18
2 open now
Primary completion
2030-11
later than 15 of 16 live
Registered
17th of 18
by date
Lead sponsor
5 of 18
GlaxoSmithKline

Among the 18 studies testing dostarlimab in Endometrial Neoplasms, this one has the largest planned enrollment, is one of 3 that started in 2026, is one of 3 in phase 3, reaches primary completion later than 15 of the 16 other live ones, and was the 17th registered.

Endometrial Neoplasms

1,428 studies on the registry are indexed under Endometrial Neoplasms; 472 are open to participants now.

Browse Endometrial Neoplasms studies →

Open to participants now

12 of the 18 studies testing dostarlimab in Endometrial Neoplasms are open now, in 4 countries. Recruiting first, the newest first:

6 more — sign in →

By country, each count listing its studies:

All 12 open studies →

About dostarlimab

dostarlimab: first FDA approval 2021 (JEMPERLI), first EMA approval 2021. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 356 Endometrial Neoplasms studies recruiting now, 266 (75%) set no upper age limit and 54 (15%) stop at 75 or younger; 26 take children under 18; 23 take healthy volunteers.

This study: 18 Years and older · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 18 studies testing dostarlimab in Endometrial Neoplasms, or all of them as a file.
02

Study summary

This is an open-label study, meaning both the researchers and participants will know which treatment is being given.

The study has two parts. In Part 1, researchers will identify the most suitable SC dose. In Part 2, participants will be randomly assigned by chance to receive dostarlimab as either an SC injection or an IV infusion. All participants will also receive carboplatin and paclitaxel. Treatment may continue for up to 3 years, with participants closely monitored throughout the study.

03

Conditions studied

  • Endometrial Carcinoma
  • Neoplasms, Endometrial

Keywords

  • Endometrial Carcinoma
  • Dostarlimab
  • Carboplatin-Paclitaxel
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participant is at least 18 years of age (or the legal age of consent in the jurisdiction in which the trial is taking place) at the time of signing the Form (ICF).
  • Participant has primary Stage III or Stage IV disease or first recurrent EC.
  • Participant must have a documented Mismatch repair (MMR)/Microsatellite Instability (MSI) status.
  • Participant is capable of giving signed informed consent, including compliance with the requirements and restrictions listed in the ICF and in the protocol.
  • Participant has an (ECOG) performance status of 0, 1, or 2 for Part 1 and an ECOG performance status of 0 or 1 for Part 2.
  • Participant has adequate organ function.

Exclusion criteria

Exclusion Criteria:

  • Participant has history of or active disease that has required systemic treatments within the 2 years prior to screening.
  • Participant has a history of severe allergic and/or anaphylactic reactions to chimeric, human or humanized antibodies, fusion proteins, or known to carboplatin, paclitaxel or dostarlimab components or .
  • Participant has received prior therapy with anti-programmed death protein 1 (), anti-programmed cell death ligand 1 (PD-L1), or anti-PD-L2 agent.
  • Participant has known uncontrolled brain or central nervous system (CNS) .
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
378 participants (estimated)

Study arms

  • Experimental
    Part 1 (Phase 1b) SC dostarlimab and IV dostarlimab

    Participants will receive SC dostarlimab in Cohorts 1, 2, 4, 5 and 6, at different doses, to determine the doses of SC dostarlimab that will yield drug exposures comparable to approved IV dosing regimens. Participants in Cohort 3 will receive IV dostarlimab. Participants in all cohorts will receive carboplatin and paclitaxel. After 6 cycles, all participants will receive IV dostarlimab for up to 3 years until progression, death, or intolerable toxicities.

    Biological: Dostarlimab · Drug: Carboplatin and paclitaxel

  • Experimental
    Part 2 (Phase 3): SC dostarlimab (experimental) or IV dostarlimab (standard of care)

    Eligible participants will be randomly assigned to receive either SC dostarlimab or IV dostarlimab (standard of care arm) in a 1:1 ratio. Participants randomized to the experimental arm will receive SC dostarlimab in combination with carboplatin and paclitaxel for 6 cycles, followed by SC dostarlimab monotherapy for up to 3 years of treatment in total. Participants randomized to the standard of care arm will receive IV dostarlimab in combination with carboplatin and paclitaxel for 6 cycles, followed by IV dostarlimab monotherapy for up to 3 years of treatment in total.

    Biological: Dostarlimab · Drug: Carboplatin and paclitaxel

Interventions

  • BiologicalDostarlimab

    Dostarlimab will be administered as SC injection and IV infusion

  • DrugCarboplatin and paclitaxel

    Drug pages: Carboplatin · Paclitaxel

    Carboplatin and paclitaxel will be administered as an IV infusion

06

What researchers measure

Primary outcomes

  1. Part 1: Serum Trough Concentration (Ctrough) After First Dose of Dostarlimab

    Time frame: Up to 42 days

  2. Part 1: Area Under the Concentration-time Curve (AUC) of Dostarlimab

    Time frame: Up to 42 days

  3. Part 2: Observed Ctrough of Dostarlimab

    Time frame: Up to 168 days

  4. Part 2: Model-predicted (MP) AUC of Dostarlimab

    Time frame: Up to 21 days

  5. Part 2: MP AUC of Dostarlimab

    Time frame: Up to 168 days

Secondary outcomes

  1. Part 1: Ctrough of Dostarlimab

    Time frame: Up to 42 days

  2. Part 1: AUC of Dostarlimab

    Time frame: Up to 42 days

  3. Part 1: Maximum Observed Concentration (Cmax) of Dostarlimab

    Time frame: Up to 42 days

  4. Part 1: Time to Peak Drug Concentration (Tmax) of Dostarlimab

    Time frame: Up to 42 days

  5. Parts 1 and 2: Number of Participants Experiencing Adverse Events (AEs), Serious AEs (SAEs), Treatment-emergent AEs (TEAEs) and Immune-mediated AEs (imAEs)

    Time frame: Up to 39 months

  6. Parts 1 and 2: Number of Participants with TEAEs Leading to Infusion or Injection Interruption, Dose Modifications, Trial Intervention Discontinuation, or Death

    Time frame: Up to 39 months

  7. Parts 1 and 2: Confirmed Overall Response Rate (ORR)

    Confirmed ORR is defined as the percentage of participants reaching confirmed complete response (CR) or confirmed partial response (PR) per RECIST 1.1 by blinded independent central review (BICR) and investigator assessment

    Time frame: Up to 3 years

  8. Parts 1 and 2: Duration of Response (DoR)

    DoR per RECIST 1.1 by BICR and investigator assessment is defined as the time from the date of first documented objective response of CR or PR that is subsequently confirmed until the date of first documented progressive disease (PD) or death due to any cause, whichever comes first

    Time frame: Up to 3 years

  9. Parts 1 and 2: Progression-free Survival (PFS)

    PFS is defined as the time from the date of randomization to the date of first documented objective tumor progression per RECIST 1.1 by BICR and investigator assessment or death due to any cause, whichever comes first

    Time frame: Up to 3 years

  10. Parts 1 and 2: Overall Survival (OS)

    OS is defined as the time from the date of randomization to the date of death due to any cause

    Time frame: Up to 3 years

  11. Part 1: Number of Participants with Antidrug Antibody (ADAs) against Dostarlimab

    Time frame: Up to 39 months

  12. Part 2: Number of Participants with ADAs against Dostarlimab

    Time frame: Up to 3 years

  13. Part 2: MP Ctrough of Dostarlimab

    Time frame: Up to 168 days

  14. Part 2: MP Ctrough at Steady State of Dostarlimab

    Time frame: Up to 168 days

  15. Part 2: MP AUC at Steady State of Dostarlimab

    Time frame: Up to 168 days

  16. Part 2: MP Cmax of Dostarlimab

    Time frame: Up to 168 days

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: Yes — Study Sponsor will assess requests from qualified researchers for anonymized individual patient-level data and related study documents. Data sharing is subject to certain criteria, conditions, and exceptions. For further information, refer to https://www.gsk-studyregister.com/gsk-patient-level-data-sharing-july2025.pdf

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report

Time frame: Anonymized IPD will be made available within 6 months of publication of primary, key secondary and safety results for studies in product with approved indication(s) or terminated asset(s) across all indications.

Access criteria: Anonymized IPD is shared with researchers whose proposals are approved by an Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months but an extension may be granted, when justified, for up to 6 months.

Data sharing details ↗ · www.gsk-studyregister.com

No publications or documents are linked to this record.

09

Timeline

2 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Nov 2026; primary completion for Nov 2030, 47 months later.

Of 44 phase 3 interventional studies under Endometrial Neoplasms, half reached primary completion within 53 months of starting (the median), counting those still running; a quarter within 45 and three quarters within 126. This study's planned 47 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 30, 2026
First posted
Oct 6, 2026
StartEst.
Nov 12, 2026
Primary completionEst.
Nov 5, 2030
CompletionEst.
Nov 5, 2032
Last update
Oct 19, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Enrollment
380→378
Oct 19, 2026
Design
Added Phase 3; removed Phase 1·Phase 2
Oct 19, 2026
Registered
First appeared on the registry
Oct 6, 2026
Show all 2 updates
  1. Oct 19, 2026
    Enrollment 380→378
    Design Added Phase 3; removed Phase 1·Phase 2
    + 2 other changes: verification date and conditions
  2. Oct 6, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07860450
Lead sponsor
GlaxoSmithKline
Responsible party
Sponsor
First posted
Oct 6, 2026
Start date
Nov 12, 2026 (estimated)
Primary completion
Nov 5, 2030 (estimated)
Completion
Nov 5, 2032 (estimated)
Last update
Oct 19, 2026

Study contacts

US GSK Clinical Trials Call Center
Contact
GSKClinicalSupportHD@gsk.com
877-379-3718
EU GSK Clinical Trials Call Center
Contact
GSKClinicalSupportHD@gsk.com
+44 (0) 20 89904466
GSK Clinical Trials
study director · GlaxoSmithKline

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Dostarlimab · Carboplatin · Paclitaxel

Start the discussion